EXO1

Across TCGA pan-cancer cohorts, EXO1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EXO1 data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher EXO1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EXO1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, UCEC, and LIHC are the cancer types where EXO1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.156	0.710	.002	24	view →
UCEC	DFS	Median	II,III,IV	1.000	0.439	.017	20	view →
LIHC	OS	Median	II,III,IV	0.174	0.700	<.001	16	view →
ESCA	DFS	Median	II,III,IV	0.175	0.525	.021	12	view →
SKCM	OS	Median	IV	0.179	0.755	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EXO1–HNSC (OS)

Open the HNSC breakdown →